With two billion people overweight or obese and the obesity treatment market expected to reach $200 billion by 2031, Olio Labs has released a groundbreaking study. The data uncover fundamental sex-based differences in how weight loss medications interact with human biology, revealing why women experience more severe side effects from GLP-1 drugs such as Ozempic? and Zepbound®.
Olio Labs‘ study uncovers unprecedented insights into GLP-1 drug effectiveness across sexes, addressing a critical research gap in a market where women make up 70% of patients.
- Breakthrough Potential: The research suggests personalized dosing—adjusting medication based on menstrual cycle phases—could reduce side effects and discontinuation rates.
- Efficacy-to-Tolerability Ratio: Women show greater weight loss than men but experience 2.5 times higher rates of nausea and vomiting.
- Biological Mechanisms Identified: The study reveals that female mice have nearly double the GLP-1 receptor expression in brain regions linked to nausea, explaining their heightened side effects. If this receptor expression pattern is consistent across species it could explain why women experience higher rates of nausea and vomiting.
- Hormone-Drug Interaction: Higher estrogen levels correlate with more severe side effects, highlighting the role of hormone levels in drug response.
- Cross-Species Validation: Findings were replicated in rats and mice, confirming these sex-based differences are evolutionarily conserved.
To learn more, read the paper On the Sex Differences in GLP-1 Signaling Across Species
